TAF II135 (AA 454-565) antibody
| Antigen | TAF II135 |
| Binding Site |
AA 454-565 |
| Clonality | Monoclonal (22) |
| Host |
Mouse |
| Reactivity |
Human |
| Application |
Western Blotting (WB), Immunofluorescence (IF)
|
![]() |
4 references available |
| Catalog no. | ABIN968728 |
| Quantity | 50 µg (250 µg/ml) |
| Price | Product not available in this region. |
| Shipping to |
|
Additional Information
| Immunogen | Human TAF[II]135 |
| Cross-Reactivity | Mouse (Murine) |
| Format | Liquid |
| Isotype | IgG1 |
| Clone | 22 |
| Description | Tightly associated factors (TAFs) play an essential role in transcriptional activation through their interaction with a variety of activators. TAF[II]135 (a.k.a. TAF[II]130) is a human homologue of Drosophila TAF[II]110, the first TAF shown to have coactivator activity. TAF[II]135 contains multiple glutamine-rich regions, as well as a coactivator domain (CAD). The glutamine-rich regions of TAF[II]135 facilitate interaction with Sp1 and CREB, which leads to enhancement of both Sp1- and CREB-mediated transcription. In addition, TAF[II]135 can potentiate transcriptional stimulation by AF-2 of the retinoic acid, thyroid hormone, and vitamine D3 receptors. However, TAF[II]135 does not interact with the AF-2s of the estrogen and retinoid X receptors. Interestingly, TAF[II]135 enhancement of CREB transcriptional activity may be disrupted by expanded polyglutamine (CAG) repeats found in at least eight different neurodegenerative disorders. Thus, TAF[II]135 may have important coactivator activities in many different transcription-regulating cell signaling pathways, and interference of TAF[II]135 activity by CAG repeats may be a common mechanism of specific types of neuropathologies. |
| Characteristics |
1. Since applications vary, each investigator should titrate the reagent to obtain optimal results. 2. Please refer to us for technical protocols. 3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing. 4. Source of all serum proteins is from USDA inspected abattoirs located in the United States. |
| Molecular Weight | 135 kDa |
| Comments |
Related Products: ABIN968537, ABIN967389 |
Application Details
| Concentration | 250 µg/ml |
| Purity | Purified |
| Purification | Purified from tissue culture supernatant or ascites by affinity chromatography. |
| Buffer | Aqueous buffered solution containing BSA, glycerol. |
| Preservative | 0.09% Sodium azide. |
| Storage | Store undiluted at -20° C. |
| Restrictions | For Research Use only |
Images
| Western blot analysis of TAF[II] 135 on Jurkat lysate. Lane 1: 1:250, lane 2: 1:500, lane 3: 1:1000 dilution of anti-TAF[II] 135. Immunofluorescent staining of HeLa cells. |
Publications
| Product |
Mengus, May, Carré et al.: "Human TAF(II)135 potentiates transcriptional activation by the AF-2s of the retinoic acid, vitamin D3, and thyroid hormone receptors in mammalian cells." in: Genes & development, Vol. 11, Issue 11, pp. 1381-95, 1997 (PubMed).
Saluja, Vassallo, Tanese: "Distinct subdomains of human TAFII130 are required for interactions with glutamine-rich transcriptional activators." in: Molecular and cellular biology, Vol. 18, Issue 10, pp. 5734-43, 1998 (PubMed). Shimohata, Nakajima, Yamada et al.: "Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription." in: Nature genetics, Vol. 26, Issue 1, pp. 29-36, 2000 (PubMed). Freiman, Albright, Chu et al.: "Redundant role of tissue-selective TAF(II)105 in B lymphocytes." in: Molecular and cellular biology, Vol. 22, Issue 18, pp. 6564-72, 2002 (PubMed). |




